Leronlimab and liver pump therapy for colorectal cancer liver metastases
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug (leronlimab) combined with standard chemotherapy delivered directly to the liver through a pump, plus systemic therapy, for people with colorectal cancer that has spread mainly to the liver. The goal is to shrink or control the liver tumors so they can be completely removed or treated, potentially leading to no evidence of disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- Your colorectal cancer has spread to your liver, and the liver tumors can be surgically removed (or treated with other liver-directed therapies) with the goal of no evidence of disease
- You have adequate liver and kidney function (based on blood tests)
- You have not had chemotherapy, immunotherapy, or targeted therapy in the last 14 days
- You can stop herbal supplements at least 14 days before starting
- You are willing to use effective birth control or abstain from sex during the study and for 3 months after
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a special chemotherapy pump implanted in your liver (hepatic arterial infusion) to standard chemotherapy works better than standard chemotherapy alone for people whose colorectal cancer has spread only to the liver and cannot be removed by surgery. The pump delivers high doses of chemo directly to the liver to shrink tumors and possibly control the disease longer.
This trial tests a treatment approach where you receive chemotherapy directly into your liver through a surgically placed pump, combined with standard systemic chemotherapy (given through a vein). The goal is to shrink liver tumors enough so they can be removed later with surgery. It is for people whose colorectal cancer has spread only to the liver and has not been treated before.
This trial tests a combination of two immunotherapy drugs (Iparomlimab and Tuvonralimab) plus another drug (Bevacizumab) and chemotherapy (CAPEOX) for people with colorectal cancer that has spread to the liver. The goal is to shrink the tumors enough to allow surgery to remove them.
This trial tests a combination treatment that uses heat or cold (ablation) to destroy liver tumors along with medicines that boost your immune system to fight cancer. It is for people whose colorectal cancer has spread to the liver and who could not have surgery, or whose first treatment stopped working.
This trial tests a new combination of drugs for people with colorectal cancer that has spread to the liver and cannot be removed by surgery. It aims to shrink or control these liver tumors.
This phase 2 study tests a liver-targeted medicine delivered through a special implanted pump, combined with standard chemo, for cancers that spread mainly to the liver. It may help control tumor growth in the liver and improve outcomes compared with standard treatment alone.
Hear when a new Metastatic Colorectal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.